For people with HIV and fatty liver disease on integrase inhibitors, taking tesamorelin for a year likely reduced liver fat by almost 5%, while the placebo group saw almost no change.

Scientific Claim

In individuals with HIV and non-alcoholic fatty liver disease on integrase inhibitor therapy, tesamorelin treatment for 12 months was likely associated with a 4.9% absolute reduction in hepatic fat fraction compared to placebo's 0.1% reduction (p=0.015), representing a 31% relative reduction from baseline.

Original Statement

“the tesamorelin treated group saw a 31% relative reduction in HFF compared to baseline (p=0.006) which was significantly higher than in the placebo treated group (T:-4.9%, P:-0.1% absolute change p=0.015).”

From study:1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV

Evidence Quality Assessment

Claim Status

appropriately stated

Study Design Support

Design supports claim

Appropriate Language Strength

probability

Can suggest probability/likelihood

Assessment Explanation

The study design (RCT) supports causal inference but with reduced confidence due to unknown blinding, so probability verbs like 'likely associated' are appropriate.

Evidence from Studies

Supporting (1)

1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV

Randomized Controlled Trial

Human

Contradicting (0)

No contradicting evidence found

Source Study

1499. Tesamorelin Reduces Visceral Adipose Tissue and Liver Fat in INSTI-Treated Persons with HIV

Score: 63

DOI: 10.1093/ofid/ofad500.1334

Similar Assertions

People with HIV and fatty liver disease on INSTI drugs who took tesamorelin for a year likely saw their liver fat decrease by 31% compared to their starting point.

99%

For people with HIV and fatty liver disease on INSTI drugs, tesamorelin likely reduces liver fat by 4.9% while placebo has almost no effect (0.1% decrease) after a year.

98%

For people with HIV and fatty liver disease on certain HIV drugs, taking tesamorelin for a year likely reduces belly fat by 8.3% while placebo makes it increase by 10.8%.

96%

For people with HIV and fatty liver on INSTI drugs, taking tesamorelin for a year likely reduces liver fat by 31% compared to their starting point, which is much better than the tiny change seen in those on a placebo.

95%

For people with HIV and fatty liver disease who are taking integrase inhibitor drugs, taking tesamorelin for a year likely helped reduce belly fat, while those on a placebo saw their belly fat increase.

95%